Literature DB >> 23172372

Expression of miR-124 inhibits growth of medulloblastoma cells.

Joachim Silber1, Rintaro Hashizume, Tristan Felix, Sujatmi Hariono, Mamie Yu, Mitchel S Berger, Jason T Huse, Scott R VandenBerg, C David James, J Graeme Hodgson, Nalin Gupta.   

Abstract

Medulloblastoma is the most common malignant brain tumor in children, and a substantial number of patients die as a result of tumor progression. Overexpression of CDK6 is present in approximately one-third of medulloblastomas and is an independent poor prognostic marker for this disease. MicroRNA (miR)-124 inhibits expression of CDK6 and prevents proliferation of glioblastoma and medulloblastoma cells in vitro. We examined the effects of miR-124 overexpression on medulloblastoma cells both in vitro and in vivo and compared cell lines that have low and high CDK6 expression. MiR-124 overexpression inhibits the proliferation of medulloblastoma cells, and this effect is mediated mostly through the action of miR-124 upon CDK6. We further show that induced expression of miR-124 potently inhibits growth of medulloblastoma xenograft tumors in rodents. Further testing of miR-124 will help define the ultimate therapeutic potential of preclinical models of medulloblastoma in conjunction with various delivery strategies for treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23172372      PMCID: PMC3534424          DOI: 10.1093/neuonc/nos281

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  32 in total

Review 1.  Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle.

Authors:  S V Ekholm; S I Reed
Journal:  Curr Opin Cell Biol       Date:  2000-12       Impact factor: 8.382

2.  A microRNA array reveals extensive regulation of microRNAs during brain development.

Authors:  Anna M Krichevsky; Kevin S King; Christine P Donahue; Konstantin Khrapko; Kenneth S Kosik
Journal:  RNA       Date:  2003-10       Impact factor: 4.942

3.  The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing.

Authors:  Eugene V Makeyev; Jiangwen Zhang; Monica A Carrasco; Tom Maniatis
Journal:  Mol Cell       Date:  2007-08-03       Impact factor: 17.970

4.  Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.

Authors:  Ryuta Saito; Michal T Krauze; Charles O Noble; Daryl C Drummond; Dmitri B Kirpotin; Mitchel S Berger; John W Park; Krystof S Bankiewicz
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

5.  Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.

Authors:  Yoji Yamashita; Michal T Krauze; Tomohiro Kawaguchi; Charles O Noble; Daryl C Drummond; John W Park; Krystof S Bankiewicz
Journal:  Neuro Oncol       Date:  2006-10-03       Impact factor: 12.300

6.  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study.

Authors:  P M Zeltzer; J M Boyett; J L Finlay; A L Albright; L B Rorke; J M Milstein; J C Allen; K R Stevens; P Stanley; H Li; J H Wisoff; J R Geyer; P McGuire-Cullen; J A Stehbens; S B Shurin; R J Packer
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

7.  Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing.

Authors:  Rintaro Hashizume; Nalin Gupta; Mitchel S Berger; Anu Banerjee; Michael D Prados; Jennifer Ayers-Ringler; C David James; Scott R VandenBerg
Journal:  Neuro Oncol       Date:  2010-01-11       Impact factor: 12.300

8.  Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma.

Authors:  Frank Mendrzyk; Bernhard Radlwimmer; Stefan Joos; Felix Kokocinski; Axel Benner; Daniel E Stange; Kai Neben; Heike Fiegler; Nigel P Carter; Guido Reifenberger; Andrey Korshunov; Peter Lichter
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

Review 9.  Management of and prognosis with medulloblastoma: therapy at a crossroads.

Authors:  Roger J Packer; Gilbert Vezina
Journal:  Arch Neurol       Date:  2008-11

10.  miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells.

Authors:  Joachim Silber; Daniel A Lim; Claudia Petritsch; Anders I Persson; Alika K Maunakea; Mamie Yu; Scott R Vandenberg; David G Ginzinger; C David James; Joseph F Costello; Gabriele Bergers; William A Weiss; Arturo Alvarez-Buylla; J Graeme Hodgson
Journal:  BMC Med       Date:  2008-06-24       Impact factor: 8.775

View more
  29 in total

Review 1.  Emerging Epigenetic Therapies for Brain Tumors.

Authors:  Lokesh Kukreja; Catherine J Li; Sathyapriya Ezhilan; Vishwanath R Iyer; John S Kuo
Journal:  Neuromolecular Med       Date:  2021-10-22       Impact factor: 3.843

2.  miR-124 regulates early isolation-induced social abnormalities via inhibiting myelinogenesis in the medial prefrontal cortex.

Authors:  Yanli Zhang; Yingting Pang; Weixi Feng; Yuxi Jin; Sijia Chen; Shixin Ding; Ze Wang; Ying Zou; Yun Li; Tianqi Wang; Peng Sun; Junying Gao; Yi Zhu; Xiaoyan Ke; Charles Marshall; Huang Huang; Chengyu Sheng; Ming Xiao
Journal:  Cell Mol Life Sci       Date:  2022-09-04       Impact factor: 9.207

3.  miR-124 functions as a tumor suppressor in the endometrial carcinoma cell line HEC-1B partly by suppressing STAT3.

Authors:  Yunyun Li; Zhongzu Zhang; Xiuxia Liu; Tingting Huang; Wenfeng He; Yang Shen; Xin Liu; Kui Hong; Qing Cao
Journal:  Mol Cell Biochem       Date:  2013-11-28       Impact factor: 3.396

4.  Lithium-induced neuroprotection in stroke involves increased miR-124 expression, reduced RE1-silencing transcription factor abundance and decreased protein deubiquitination by GSK3β inhibition-independent pathways.

Authors:  Thorsten R Doeppner; Britta Kaltwasser; Eduardo H Sanchez-Mendoza; Ahmet B Caglayan; Mathias Bähr; Dirk M Hermann
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-21       Impact factor: 6.200

5.  The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma.

Authors:  Amanda Tivnan; Jack Zhao; Terrance G Johns; Bryan W Day; Brett W Stringer; Andrew W Boyd; Sarita Tiwari; Keith M Giles; Charlie Teo; Kerrie L McDonald
Journal:  Tumour Biol       Date:  2013-09-26

6.  miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma.

Authors:  Jun Wei; Fei Wang; Ling-Yuan Kong; Shuo Xu; Tiffany Doucette; Sherise D Ferguson; Yuhui Yang; Kayla McEnery; Krishan Jethwa; Olsi Gjyshi; Wei Qiao; Nicholas B Levine; Frederick F Lang; Ganesh Rao; Gregory N Fuller; George A Calin; Amy B Heimberger
Journal:  Cancer Res       Date:  2013-05-01       Impact factor: 12.701

Review 7.  miR miR on the wall, who's the most malignant medulloblastoma miR of them all?

Authors:  Xin Wang; Borja L Holgado; Vijay Ramaswamy; Stephen Mack; Kory Zayne; Marc Remke; Xiaochong Wu; Livia Garzia; Craig Daniels; Anna M Kenney; Michael D Taylor
Journal:  Neuro Oncol       Date:  2018-02-19       Impact factor: 12.300

Review 8.  Medulloblastomics revisited: biological and clinical insights from thousands of patients.

Authors:  Volker Hovestadt; Olivier Ayrault; Fredrik J Swartling; Giles W Robinson; Stefan M Pfister; Paul A Northcott
Journal:  Nat Rev Cancer       Date:  2019-12-09       Impact factor: 69.800

Review 9.  Epigenetic-Based Therapy-A Prospective Chance for Medulloblastoma Patients' Recovery.

Authors:  Agata Strejczek; Dawid Woszczyk; Helena Urbaniak; Martyna Różańska; Michał Robak; Zofia Matuszewska; Anna-Maria Barciszewska
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923

Review 10.  Tumor Suppressive Effects of miR-124 and Its Function in Neuronal Development.

Authors:  Rikako Sanuki; Tomonori Yamamura
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.